adalimumab + placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hidradenitis Suppurativa (HS)

Conditions

Hidradenitis Suppurativa (HS)

Trial Timeline

Nov 1, 2011 → Jan 1, 2014

NCT ID

NCT01468207

About adalimumab + placebo

adalimumab + placebo is a phase 3 stage product being developed by AbbVie for Hidradenitis Suppurativa (HS). The current trial status is completed. This product is registered under clinical trial identifier NCT01468207. Target conditions include Hidradenitis Suppurativa (HS).

What happened to similar drugs?

1 of 20 similar drugs in Hidradenitis Suppurativa (HS) were approved

Approved (1) Terminated (0) Active (19)

✅Placebo + AdalimumabAbbVieApproved

🔄SonelokimabMoonLake ImmunotherapeuticsPhase 3

🔄Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3

🔄Lutikizumab + PlaceboAbbViePhase 3

🔄Upadacitinib + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02065557	Phase 3	Completed	Oct 13, 2014	Feb 7, 2020	Ulcerative Colitis
NCT02065570	Phase 3	Completed	May 1, 2014	Jan 30, 2020	Crohn's Disease
NCT01893996	Approved	Completed	Jul 1, 2013	Jul 1, 2017	Rheumatoid Arthritis
NCT01808118	Phase 3	Completed	Apr 16, 2013	Apr 14, 2017	Axial Spondyloarthritis
NCT01670240	Phase 3	Completed	Aug 1, 2012	Jan 1, 2016	Ulcerative Colitis
NCT01646073	Phase 3	Completed	Aug 1, 2012	Dec 1, 2013	Plaque Psoriasis
NCT01468207	Phase 3	Completed	Nov 1, 2011	Jan 1, 2014	Hidradenitis Suppurativa (HS)
NCT01468233	Phase 3	Completed	Nov 1, 2011	Apr 1, 2014	Hidradenitis Suppurativa (HS)
NCT01064856	Phase 3	Completed	Feb 1, 2010	May 1, 2014	Peripheral Spondyloarthritis

Competing Products

20 competing products in Hidradenitis Suppurativa (HS)

See all competitors

Product	Company	Stage	Hype Score
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	41
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	41
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	38
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	38
Sonelokimab (M1095) + Adalimumab	MoonLake Immunotherapeutics	Phase 2	29
Eltrekibart + Placebo	Eli Lilly	Phase 2	39
Placebo + LY3041658	Eli Lilly	Phase 2	35
Placebo + Adalimumab	AbbVie	Approved	43
Lutikizumab + Placebo	AbbVie	Phase 3	47
Adalimumab	AbbVie	Pre-clinical	26
Upadacitinib + Placebo	AbbVie	Phase 3	47
Lutikizumab	AbbVie	Phase 2	42
adalimumab	AbbVie	Phase 3	40
Lutikizumab + Placebo	AbbVie	Phase 2	39
Risankizumab + Placebo for risankizumab	AbbVie	Phase 2	35
adalimumab	AbbVie	Phase 3	40
adalimumab + placebo	AbbVie	Phase 3	40
Upadacitinib + Placebo	AbbVie	Phase 2	35
MEDI8968 + Saline	AstraZeneca	Phase 2	27
Anifrolumab	AstraZeneca	Phase 2	39